Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Perfusion Imaging | 115 | 2024 | 571 | 20.630 |
Why?
|
Coronary Artery Disease | 167 | 2024 | 6659 | 12.250 |
Why?
|
Coronary Circulation | 80 | 2024 | 1577 | 11.840 |
Why?
|
Fractional Flow Reserve, Myocardial | 37 | 2024 | 329 | 10.530 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 84 | 2024 | 1067 | 10.010 |
Why?
|
Positron-Emission Tomography | 142 | 2024 | 6465 | 9.610 |
Why?
|
Coronary Angiography | 96 | 2024 | 4563 | 6.470 |
Why?
|
Myocardial Ischemia | 41 | 2023 | 2164 | 5.270 |
Why?
|
Nuclear Medicine | 18 | 2024 | 236 | 4.910 |
Why?
|
Cardiology | 28 | 2024 | 1723 | 4.170 |
Why?
|
Coronary Vessels | 38 | 2024 | 3112 | 3.920 |
Why?
|
Heart | 42 | 2024 | 4393 | 3.840 |
Why?
|
Microcirculation | 17 | 2024 | 1278 | 3.760 |
Why?
|
Rubidium Radioisotopes | 22 | 2018 | 76 | 3.710 |
Why?
|
Coronary Stenosis | 27 | 2023 | 820 | 3.480 |
Why?
|
Cardiomyopathies | 32 | 2024 | 1952 | 3.400 |
Why?
|
Tomography, X-Ray Computed | 76 | 2024 | 20509 | 3.010 |
Why?
|
Sarcoidosis | 14 | 2019 | 520 | 3.000 |
Why?
|
Diagnostic Techniques, Cardiovascular | 9 | 2021 | 152 | 2.570 |
Why?
|
Exercise Test | 44 | 2023 | 2128 | 2.380 |
Why?
|
Ammonia | 11 | 2023 | 236 | 2.260 |
Why?
|
Tomography, Emission-Computed | 26 | 2024 | 1121 | 2.220 |
Why?
|
Myocardial Infarction | 48 | 2024 | 11891 | 2.020 |
Why?
|
Ventricular Dysfunction, Left | 23 | 2020 | 2128 | 2.000 |
Why?
|
Ventricular Function, Left | 28 | 2024 | 3880 | 1.880 |
Why?
|
Amyloidosis | 14 | 2023 | 817 | 1.780 |
Why?
|
Coronary Disease | 25 | 2019 | 5990 | 1.720 |
Why?
|
Ventricular Remodeling | 10 | 2022 | 1261 | 1.700 |
Why?
|
Fluorodeoxyglucose F18 | 26 | 2024 | 2007 | 1.690 |
Why?
|
Predictive Value of Tests | 70 | 2024 | 15289 | 1.670 |
Why?
|
Cardiovascular Diseases | 34 | 2024 | 15757 | 1.490 |
Why?
|
Molecular Imaging | 7 | 2024 | 818 | 1.450 |
Why?
|
Diagnostic Imaging | 12 | 2024 | 3527 | 1.450 |
Why?
|
Stroke Volume | 25 | 2023 | 5523 | 1.420 |
Why?
|
Cardiac Imaging Techniques | 7 | 2024 | 269 | 1.410 |
Why?
|
Humans | 404 | 2024 | 760621 | 1.380 |
Why?
|
Plaque, Atherosclerotic | 12 | 2023 | 1518 | 1.380 |
Why?
|
Radiopharmaceuticals | 39 | 2024 | 2634 | 1.350 |
Why?
|
Heart Transplantation | 9 | 2024 | 3224 | 1.340 |
Why?
|
Prognosis | 92 | 2024 | 29658 | 1.300 |
Why?
|
Myocardium | 26 | 2024 | 4700 | 1.240 |
Why?
|
Myocardial Revascularization | 16 | 2021 | 841 | 1.230 |
Why?
|
Registries | 47 | 2024 | 8469 | 1.200 |
Why?
|
Heart Diseases | 10 | 2022 | 2809 | 1.180 |
Why?
|
Microvessels | 6 | 2024 | 572 | 1.170 |
Why?
|
Diabetic Angiopathies | 9 | 2019 | 822 | 1.170 |
Why?
|
Vasodilator Agents | 19 | 2021 | 978 | 1.160 |
Why?
|
Perfusion | 18 | 2024 | 1376 | 1.120 |
Why?
|
Middle Aged | 187 | 2024 | 220352 | 1.070 |
Why?
|
Aged | 153 | 2024 | 169152 | 1.050 |
Why?
|
Ethylene Glycols | 8 | 2024 | 190 | 1.040 |
Why?
|
Vascular Resistance | 8 | 2024 | 933 | 1.030 |
Why?
|
Male | 226 | 2024 | 359744 | 1.030 |
Why?
|
Female | 227 | 2024 | 391270 | 1.030 |
Why?
|
Subtraction Technique | 7 | 2013 | 510 | 1.030 |
Why?
|
Risk Assessment | 53 | 2024 | 24123 | 0.990 |
Why?
|
Cadmium | 4 | 2022 | 215 | 0.980 |
Why?
|
Periodicals as Topic | 4 | 2018 | 1469 | 0.950 |
Why?
|
Heart Failure | 22 | 2024 | 11847 | 0.950 |
Why?
|
Awards and Prizes | 3 | 2018 | 359 | 0.930 |
Why?
|
Dideoxynucleosides | 2 | 2023 | 132 | 0.890 |
Why?
|
Tellurium | 3 | 2020 | 21 | 0.890 |
Why?
|
Heart Valve Prosthesis | 5 | 2022 | 1495 | 0.860 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 36 | 0.830 |
Why?
|
Vasodilation | 8 | 2012 | 962 | 0.810 |
Why?
|
Technetium Tc 99m Pyrophosphate | 3 | 2020 | 45 | 0.810 |
Why?
|
Thallium Radioisotopes | 3 | 2019 | 138 | 0.810 |
Why?
|
Technetium Tc 99m Sestamibi | 9 | 2022 | 173 | 0.800 |
Why?
|
Zinc | 4 | 2022 | 689 | 0.790 |
Why?
|
Aniline Compounds | 8 | 2024 | 1069 | 0.770 |
Why?
|
Oxazines | 1 | 2023 | 341 | 0.760 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2024 | 2290 | 0.750 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 279 | 0.740 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 558 | 0.720 |
Why?
|
Image Interpretation, Computer-Assisted | 16 | 2021 | 3340 | 0.700 |
Why?
|
Cardiovascular System | 3 | 2024 | 850 | 0.680 |
Why?
|
Risk Factors | 72 | 2024 | 74359 | 0.680 |
Why?
|
Sensitivity and Specificity | 33 | 2024 | 14660 | 0.660 |
Why?
|
Reproducibility of Results | 37 | 2024 | 20080 | 0.650 |
Why?
|
Hypertension | 5 | 2024 | 8594 | 0.640 |
Why?
|
Calcinosis | 5 | 2014 | 1476 | 0.640 |
Why?
|
Radionuclide Imaging | 10 | 2023 | 1975 | 0.620 |
Why?
|
Myocarditis | 4 | 2019 | 766 | 0.620 |
Why?
|
Death, Sudden, Cardiac | 7 | 2018 | 1572 | 0.620 |
Why?
|
Receptors, Somatostatin | 1 | 2019 | 136 | 0.620 |
Why?
|
Constriction, Pathologic | 5 | 2023 | 1098 | 0.620 |
Why?
|
Pyridones | 1 | 2023 | 792 | 0.610 |
Why?
|
Electrons | 1 | 2019 | 264 | 0.610 |
Why?
|
Retrospective Studies | 57 | 2024 | 80372 | 0.610 |
Why?
|
Thoracic Neoplasms | 1 | 2020 | 266 | 0.600 |
Why?
|
Aortitis | 2 | 2016 | 74 | 0.600 |
Why?
|
Troponin | 3 | 2018 | 516 | 0.600 |
Why?
|
Organometallic Compounds | 2 | 2019 | 662 | 0.590 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2065 | 0.590 |
Why?
|
Diabetes Mellitus | 9 | 2024 | 5889 | 0.590 |
Why?
|
Bioprosthesis | 1 | 2022 | 600 | 0.590 |
Why?
|
Electrocardiography | 21 | 2022 | 6414 | 0.570 |
Why?
|
Heart Failure, Diastolic | 1 | 2018 | 76 | 0.570 |
Why?
|
Kidney Failure, Chronic | 4 | 2018 | 2471 | 0.560 |
Why?
|
Rheumatology | 1 | 2023 | 611 | 0.560 |
Why?
|
Regional Blood Flow | 4 | 2018 | 1490 | 0.560 |
Why?
|
Severity of Illness Index | 35 | 2024 | 15840 | 0.550 |
Why?
|
Magnetic Resonance Imaging, Cine | 8 | 2024 | 1046 | 0.540 |
Why?
|
Fluorine Radioisotopes | 5 | 2020 | 413 | 0.540 |
Why?
|
Arthritis, Rheumatoid | 5 | 2024 | 3763 | 0.540 |
Why?
|
Gamma Cameras | 3 | 2019 | 34 | 0.540 |
Why?
|
Lipoprotein(a) | 5 | 2024 | 499 | 0.530 |
Why?
|
Follow-Up Studies | 39 | 2023 | 39261 | 0.530 |
Why?
|
Cardiovascular Agents | 3 | 2017 | 867 | 0.510 |
Why?
|
Technology Assessment, Biomedical | 3 | 2008 | 306 | 0.500 |
Why?
|
Angioplasty, Balloon | 1 | 2019 | 597 | 0.500 |
Why?
|
Psoriasis | 2 | 2021 | 940 | 0.500 |
Why?
|
Ventricular Dysfunction, Right | 5 | 2024 | 615 | 0.500 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2020 | 854 | 0.500 |
Why?
|
Coronary Artery Bypass | 7 | 2014 | 2272 | 0.490 |
Why?
|
Blood Flow Velocity | 7 | 2018 | 1377 | 0.490 |
Why?
|
American Heart Association | 6 | 2022 | 1081 | 0.490 |
Why?
|
Prospective Studies | 48 | 2024 | 54303 | 0.490 |
Why?
|
Pre-Eclampsia | 1 | 2024 | 1229 | 0.470 |
Why?
|
Skin Diseases | 1 | 2023 | 1089 | 0.470 |
Why?
|
Prosthesis-Related Infections | 2 | 2019 | 487 | 0.470 |
Why?
|
Image Processing, Computer-Assisted | 15 | 2024 | 8950 | 0.460 |
Why?
|
Myocardial Stunning | 3 | 2008 | 66 | 0.450 |
Why?
|
Chest Pain | 6 | 2022 | 1106 | 0.450 |
Why?
|
Magnetic Resonance Imaging | 22 | 2024 | 36290 | 0.450 |
Why?
|
Atherosclerosis | 9 | 2024 | 3517 | 0.450 |
Why?
|
Image Enhancement | 5 | 2015 | 2881 | 0.440 |
Why?
|
Heart Ventricles | 10 | 2024 | 3811 | 0.440 |
Why?
|
Leadership | 1 | 2022 | 1371 | 0.430 |
Why?
|
Biomedical Research | 3 | 2020 | 3426 | 0.430 |
Why?
|
Piperazines | 1 | 2023 | 2525 | 0.430 |
Why?
|
Peer Review, Research | 1 | 2016 | 340 | 0.410 |
Why?
|
Adenosine | 9 | 2011 | 834 | 0.410 |
Why?
|
Troponin T | 5 | 2024 | 774 | 0.400 |
Why?
|
Calcium | 7 | 2023 | 5725 | 0.390 |
Why?
|
Endocarditis | 1 | 2015 | 351 | 0.380 |
Why?
|
Radioisotopes | 4 | 2023 | 495 | 0.380 |
Why?
|
Pericarditis | 2 | 2016 | 135 | 0.380 |
Why?
|
Aged, 80 and over | 31 | 2024 | 58995 | 0.380 |
Why?
|
Validation Studies as Topic | 2 | 2008 | 162 | 0.380 |
Why?
|
Iron Radioisotopes | 2 | 2021 | 19 | 0.370 |
Why?
|
Cause of Death | 10 | 2021 | 3725 | 0.370 |
Why?
|
Prealbumin | 5 | 2022 | 222 | 0.370 |
Why?
|
Ticlopidine | 1 | 2015 | 895 | 0.340 |
Why?
|
Echocardiography | 12 | 2023 | 4981 | 0.340 |
Why?
|
Peripheral Arterial Disease | 2 | 2019 | 1306 | 0.340 |
Why?
|
Feasibility Studies | 11 | 2023 | 5201 | 0.340 |
Why?
|
Defibrillators, Implantable | 2 | 2018 | 1499 | 0.330 |
Why?
|
Radiation Dosage | 3 | 2015 | 1958 | 0.330 |
Why?
|
Heart Atria | 4 | 2021 | 1346 | 0.320 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 5 | 2024 | 1215 | 0.320 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4215 | 0.310 |
Why?
|
Gated Blood-Pool Imaging | 2 | 2007 | 42 | 0.310 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2159 | 0.310 |
Why?
|
Amyloid Neuropathies, Familial | 3 | 2022 | 150 | 0.310 |
Why?
|
Iopamidol | 2 | 2008 | 186 | 0.310 |
Why?
|
Aortic Valve Insufficiency | 3 | 2016 | 584 | 0.310 |
Why?
|
Editorial Policies | 1 | 2013 | 457 | 0.310 |
Why?
|
Cardiomyopathy, Dilated | 3 | 2019 | 819 | 0.310 |
Why?
|
Recovery of Function | 4 | 2020 | 2985 | 0.310 |
Why?
|
Hemodynamics | 13 | 2019 | 4174 | 0.310 |
Why?
|
ROC Curve | 13 | 2024 | 3568 | 0.310 |
Why?
|
Disease-Free Survival | 8 | 2019 | 6828 | 0.310 |
Why?
|
Time Factors | 26 | 2024 | 40165 | 0.300 |
Why?
|
Extracellular Matrix | 2 | 2013 | 1726 | 0.300 |
Why?
|
Contrast Media | 10 | 2021 | 5305 | 0.300 |
Why?
|
Thrombosis | 1 | 2022 | 3052 | 0.300 |
Why?
|
Adult | 66 | 2024 | 219994 | 0.300 |
Why?
|
Magnetic Resonance Angiography | 3 | 2014 | 1431 | 0.300 |
Why?
|
Coronary Vessel Anomalies | 3 | 2016 | 317 | 0.300 |
Why?
|
Perfusion Imaging | 1 | 2009 | 196 | 0.290 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1827 | 0.290 |
Why?
|
Societies, Medical | 9 | 2021 | 3905 | 0.290 |
Why?
|
Ventricular Outflow Obstruction | 2 | 2021 | 265 | 0.280 |
Why?
|
Evidence-Based Medicine | 3 | 2013 | 3696 | 0.280 |
Why?
|
Tomography, X-Ray | 1 | 2006 | 60 | 0.280 |
Why?
|
Proportional Hazards Models | 16 | 2022 | 12531 | 0.280 |
Why?
|
Chi-Square Distribution | 9 | 2017 | 3465 | 0.270 |
Why?
|
Natriuretic Peptide, Brain | 3 | 2024 | 1717 | 0.260 |
Why?
|
Renal Dialysis | 1 | 2015 | 1801 | 0.260 |
Why?
|
Organotechnetium Compounds | 2 | 2018 | 129 | 0.260 |
Why?
|
Oxygen Consumption | 5 | 2021 | 1843 | 0.260 |
Why?
|
Inflammation | 10 | 2024 | 10756 | 0.250 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2014 | 1311 | 0.250 |
Why?
|
Organophosphorus Compounds | 2 | 2018 | 202 | 0.240 |
Why?
|
Heart Rate | 7 | 2018 | 4179 | 0.240 |
Why?
|
Prevalence | 14 | 2024 | 15687 | 0.240 |
Why?
|
Multivariate Analysis | 10 | 2017 | 12159 | 0.240 |
Why?
|
Hodgkin Disease | 2 | 2015 | 1378 | 0.240 |
Why?
|
Case-Control Studies | 13 | 2023 | 22053 | 0.240 |
Why?
|
Angina, Unstable | 2 | 2019 | 926 | 0.230 |
Why?
|
Dideoxyadenosine | 1 | 2023 | 14 | 0.230 |
Why?
|
Review Literature as Topic | 2 | 2018 | 349 | 0.230 |
Why?
|
Myocardial Bridging | 1 | 2023 | 11 | 0.230 |
Why?
|
Isosorbide Dinitrate | 1 | 2003 | 37 | 0.230 |
Why?
|
Patient Selection | 7 | 2021 | 4283 | 0.230 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1931 | 0.230 |
Why?
|
Immunoglobulin Light Chains | 3 | 2024 | 286 | 0.230 |
Why?
|
Natural Language Processing | 2 | 2024 | 1135 | 0.230 |
Why?
|
Survival Rate | 13 | 2020 | 12808 | 0.220 |
Why?
|
Treatment Outcome | 23 | 2024 | 65017 | 0.220 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2017 | 278 | 0.220 |
Why?
|
Cohort Studies | 19 | 2022 | 41335 | 0.210 |
Why?
|
Artifacts | 2 | 2011 | 1898 | 0.210 |
Why?
|
Pericardium | 3 | 2017 | 675 | 0.210 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 2 | 1999 | 537 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 7 | 2019 | 6544 | 0.210 |
Why?
|
Exercise Tolerance | 3 | 2017 | 830 | 0.200 |
Why?
|
Macrophages | 6 | 2015 | 5745 | 0.200 |
Why?
|
Troponin I | 1 | 2007 | 638 | 0.200 |
Why?
|
Probability | 3 | 2018 | 2475 | 0.200 |
Why?
|
Comorbidity | 9 | 2021 | 10551 | 0.200 |
Why?
|
Art | 1 | 2002 | 64 | 0.200 |
Why?
|
Cholesterol, LDL | 4 | 2021 | 2420 | 0.200 |
Why?
|
Nitrogen Radioisotopes | 6 | 2018 | 41 | 0.200 |
Why?
|
Lamivudine | 1 | 2023 | 363 | 0.200 |
Why?
|
Cyclopropanes | 1 | 2023 | 431 | 0.200 |
Why?
|
Peptide Fragments | 3 | 2024 | 5125 | 0.200 |
Why?
|
Quality Control | 4 | 2021 | 828 | 0.200 |
Why?
|
Amyloid | 4 | 2023 | 842 | 0.200 |
Why?
|
Skeletal Muscle Ventricle | 1 | 2001 | 3 | 0.190 |
Why?
|
Survival Analysis | 11 | 2018 | 10182 | 0.190 |
Why?
|
Acute Coronary Syndrome | 2 | 2016 | 2365 | 0.190 |
Why?
|
Heart Neoplasms | 2 | 2019 | 360 | 0.190 |
Why?
|
Radiographic Image Enhancement | 1 | 2006 | 875 | 0.190 |
Why?
|
Alanine | 1 | 2023 | 606 | 0.190 |
Why?
|
Glomerular Filtration Rate | 3 | 2017 | 2180 | 0.180 |
Why?
|
Drug Substitution | 1 | 2023 | 296 | 0.180 |
Why?
|
Carotid Artery Diseases | 2 | 2019 | 883 | 0.180 |
Why?
|
Presenilin-1 | 2 | 2021 | 660 | 0.180 |
Why?
|
Gamma Rays | 1 | 2021 | 317 | 0.180 |
Why?
|
Systems Integration | 3 | 2007 | 426 | 0.180 |
Why?
|
Radiotherapy | 1 | 2007 | 1504 | 0.180 |
Why?
|
Myocardial Contraction | 5 | 2014 | 1516 | 0.180 |
Why?
|
Obesity | 7 | 2024 | 12922 | 0.180 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2018 | 12293 | 0.170 |
Why?
|
Observer Variation | 5 | 2016 | 2601 | 0.170 |
Why?
|
Drug Combinations | 2 | 2023 | 2025 | 0.170 |
Why?
|
Science | 1 | 2002 | 239 | 0.170 |
Why?
|
Amyloidogenic Proteins | 2 | 2023 | 151 | 0.170 |
Why?
|
Heart Injuries | 1 | 2021 | 208 | 0.170 |
Why?
|
D-Amino-Acid Oxidase | 1 | 2019 | 26 | 0.170 |
Why?
|
Metabolic Diseases | 1 | 2006 | 686 | 0.170 |
Why?
|
Thorax | 1 | 2022 | 553 | 0.170 |
Why?
|
Purines | 2 | 2013 | 605 | 0.170 |
Why?
|
Diamond | 1 | 2018 | 14 | 0.160 |
Why?
|
Aortic Valve | 2 | 2022 | 1996 | 0.160 |
Why?
|
Boston | 9 | 2019 | 9280 | 0.160 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2021 | 1582 | 0.160 |
Why?
|
Quality of Life | 2 | 2022 | 13308 | 0.160 |
Why?
|
Fibrosis | 2 | 2023 | 2042 | 0.150 |
Why?
|
Models, Cardiovascular | 4 | 2015 | 978 | 0.150 |
Why?
|
Ventricular Function | 2 | 2019 | 408 | 0.150 |
Why?
|
Echocardiography, Doppler | 2 | 2020 | 901 | 0.150 |
Why?
|
Premenopause | 1 | 2002 | 1038 | 0.150 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 8056 | 0.150 |
Why?
|
Tissue Survival | 2 | 2014 | 119 | 0.150 |
Why?
|
Monocytes | 4 | 2021 | 2575 | 0.150 |
Why?
|
Hydroxychloroquine | 1 | 2022 | 427 | 0.150 |
Why?
|
Sympathetic Nervous System | 2 | 1999 | 520 | 0.150 |
Why?
|
Credentialing | 3 | 2022 | 115 | 0.150 |
Why?
|
Angina Pectoris | 1 | 2022 | 969 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 3334 | 0.150 |
Why?
|
United States | 25 | 2023 | 72461 | 0.150 |
Why?
|
Incidence | 11 | 2024 | 21392 | 0.150 |
Why?
|
Sex Characteristics | 2 | 2021 | 2629 | 0.150 |
Why?
|
Arrhythmias, Cardiac | 4 | 2018 | 2255 | 0.140 |
Why?
|
Water | 1 | 2023 | 1407 | 0.140 |
Why?
|
Postpartum Period | 1 | 2024 | 1167 | 0.140 |
Why?
|
HIV Infections | 1 | 2023 | 17165 | 0.140 |
Why?
|
Leukocyte Count | 1 | 2021 | 1600 | 0.140 |
Why?
|
Sex Factors | 9 | 2024 | 10547 | 0.140 |
Why?
|
Transposition of Great Vessels | 1 | 2001 | 590 | 0.140 |
Why?
|
Hyperemia | 5 | 2014 | 221 | 0.140 |
Why?
|
Breast Neoplasms | 2 | 2021 | 21025 | 0.140 |
Why?
|
Statistics, Nonparametric | 4 | 2016 | 2852 | 0.140 |
Why?
|
Prosthesis Failure | 1 | 2022 | 1206 | 0.140 |
Why?
|
Space Flight | 1 | 2019 | 214 | 0.140 |
Why?
|
Autonomic Nervous System Diseases | 1 | 1999 | 269 | 0.140 |
Why?
|
Ischemia | 2 | 2022 | 1893 | 0.140 |
Why?
|
Physical Examination | 1 | 2022 | 1244 | 0.140 |
Why?
|
Behavior, Animal | 2 | 2021 | 1866 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 435 | 0.140 |
Why?
|
Pilot Projects | 5 | 2023 | 8555 | 0.130 |
Why?
|
Double-Blind Method | 6 | 2018 | 12427 | 0.130 |
Why?
|
Antirheumatic Agents | 2 | 2024 | 1374 | 0.130 |
Why?
|
Retinal Artery | 1 | 2016 | 109 | 0.130 |
Why?
|
Analysis of Variance | 4 | 2014 | 6238 | 0.130 |
Why?
|
Embolism | 1 | 2019 | 408 | 0.130 |
Why?
|
Hypolipidemic Agents | 1 | 2020 | 626 | 0.130 |
Why?
|
Hydrogen Peroxide | 1 | 2019 | 732 | 0.130 |
Why?
|
Sinus of Valsalva | 1 | 2016 | 60 | 0.130 |
Why?
|
Prosthesis Fitting | 1 | 2015 | 75 | 0.130 |
Why?
|
Diabetic Neuropathies | 1 | 1999 | 406 | 0.130 |
Why?
|
Protease Inhibitors | 1 | 2019 | 755 | 0.130 |
Why?
|
Rubidium | 1 | 2015 | 122 | 0.130 |
Why?
|
Age Factors | 9 | 2024 | 18416 | 0.130 |
Why?
|
Physical Endurance | 1 | 2017 | 363 | 0.120 |
Why?
|
Kidney | 2 | 2023 | 7064 | 0.120 |
Why?
|
Endocarditis, Bacterial | 1 | 2019 | 445 | 0.120 |
Why?
|
Fungal Proteins | 1 | 2019 | 911 | 0.120 |
Why?
|
Dipyridamole | 2 | 2009 | 143 | 0.120 |
Why?
|
Software | 4 | 2019 | 4419 | 0.120 |
Why?
|
Body Mass Index | 4 | 2017 | 12914 | 0.120 |
Why?
|
Baltimore | 1 | 2015 | 230 | 0.120 |
Why?
|
Obesity, Morbid | 1 | 2006 | 1287 | 0.120 |
Why?
|
Animals | 19 | 2021 | 167963 | 0.120 |
Why?
|
Oxygen | 1 | 2006 | 4193 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 2018 | 460 | 0.120 |
Why?
|
Diastole | 1 | 2017 | 788 | 0.120 |
Why?
|
Cross-Over Studies | 2 | 2017 | 2061 | 0.120 |
Why?
|
Hyperglycemia | 1 | 2003 | 1380 | 0.120 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2018 | 347 | 0.120 |
Why?
|
Carbazoles | 1 | 2015 | 220 | 0.120 |
Why?
|
Decision Making | 3 | 2014 | 3925 | 0.120 |
Why?
|
Receptors, CCR2 | 1 | 2015 | 215 | 0.110 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2019 | 396 | 0.110 |
Why?
|
Aortography | 1 | 2015 | 420 | 0.110 |
Why?
|
Eligibility Determination | 1 | 2017 | 421 | 0.110 |
Why?
|
Meglumine | 1 | 2014 | 145 | 0.110 |
Why?
|
Marijuana Abuse | 1 | 2018 | 411 | 0.110 |
Why?
|
Arteries | 1 | 2019 | 1126 | 0.110 |
Why?
|
Receptors, GABA | 1 | 2015 | 305 | 0.110 |
Why?
|
Carbon Radioisotopes | 3 | 2000 | 557 | 0.110 |
Why?
|
Cardiac-Gated Imaging Techniques | 1 | 2014 | 140 | 0.110 |
Why?
|
Alzheimer Disease | 3 | 2021 | 8547 | 0.110 |
Why?
|
Stress, Physiological | 3 | 2018 | 1398 | 0.110 |
Why?
|
Diabetes Mellitus, Type 1 | 3 | 2003 | 3455 | 0.110 |
Why?
|
Algorithms | 10 | 2021 | 13981 | 0.110 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2897 | 0.110 |
Why?
|
Postmenopause | 1 | 2002 | 2509 | 0.110 |
Why?
|
Tetrazoles | 1 | 2019 | 905 | 0.110 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 521 | 0.110 |
Why?
|
C-Reactive Protein | 4 | 2024 | 3839 | 0.110 |
Why?
|
Mitral Valve | 2 | 2021 | 1486 | 0.110 |
Why?
|
Massachusetts | 8 | 2020 | 8803 | 0.110 |
Why?
|
Respiratory Rate | 1 | 2014 | 175 | 0.110 |
Why?
|
Collateral Circulation | 1 | 1994 | 292 | 0.110 |
Why?
|
Hematopoietic Stem Cells | 2 | 2015 | 3387 | 0.100 |
Why?
|
Radiology | 1 | 2006 | 2102 | 0.100 |
Why?
|
Adenosine A2 Receptor Agonists | 1 | 2012 | 30 | 0.100 |
Why?
|
Endothelial Cells | 2 | 2011 | 3539 | 0.100 |
Why?
|
Blood Pressure | 5 | 2016 | 8525 | 0.100 |
Why?
|
Biopsy | 3 | 2019 | 6771 | 0.100 |
Why?
|
Pyrazoles | 2 | 2013 | 1999 | 0.100 |
Why?
|
Societies, Scientific | 1 | 2013 | 221 | 0.100 |
Why?
|
Glucose | 3 | 2011 | 4351 | 0.100 |
Why?
|
Myocardial Reperfusion | 2 | 2006 | 347 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25942 | 0.100 |
Why?
|
Uric Acid | 1 | 2018 | 806 | 0.100 |
Why?
|
Area Under Curve | 4 | 2016 | 1636 | 0.100 |
Why?
|
Risk | 5 | 2020 | 9631 | 0.100 |
Why?
|
Gadolinium | 1 | 2016 | 959 | 0.100 |
Why?
|
Echocardiography, Transesophageal | 3 | 2019 | 1108 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1416 | 0.090 |
Why?
|
Mitral Valve Insufficiency | 2 | 2019 | 1419 | 0.090 |
Why?
|
Whole Body Imaging | 2 | 2010 | 278 | 0.090 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 730 | 0.090 |
Why?
|
Radiation Protection | 1 | 2015 | 425 | 0.090 |
Why?
|
Sulfonic Acids | 1 | 2011 | 102 | 0.090 |
Why?
|
Research Design | 4 | 2021 | 6180 | 0.090 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2884 | 0.090 |
Why?
|
Capillary Permeability | 1 | 2014 | 768 | 0.090 |
Why?
|
Enalapril | 3 | 2018 | 313 | 0.090 |
Why?
|
Spironolactone | 1 | 2014 | 411 | 0.090 |
Why?
|
Myocytes, Cardiac | 1 | 2019 | 1657 | 0.090 |
Why?
|
Death | 2 | 2012 | 678 | 0.090 |
Why?
|
Myeloid Cells | 1 | 2015 | 820 | 0.090 |
Why?
|
Energy Metabolism | 2 | 2019 | 2869 | 0.090 |
Why?
|
Athletes | 1 | 2017 | 1125 | 0.090 |
Why?
|
Congresses as Topic | 1 | 2015 | 805 | 0.090 |
Why?
|
Logistic Models | 4 | 2016 | 13314 | 0.090 |
Why?
|
Acetates | 1 | 2011 | 321 | 0.090 |
Why?
|
Carotid Arteries | 1 | 2014 | 951 | 0.090 |
Why?
|
Factor Analysis, Statistical | 1 | 2012 | 998 | 0.080 |
Why?
|
Autonomic Nervous System | 1 | 2015 | 697 | 0.080 |
Why?
|
Acetamides | 1 | 2011 | 256 | 0.080 |
Why?
|
Coronary Aneurysm | 1 | 2012 | 233 | 0.080 |
Why?
|
Aortic Diseases | 1 | 2015 | 736 | 0.080 |
Why?
|
Cardiotonic Agents | 1 | 2012 | 546 | 0.080 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2009 | 45 | 0.080 |
Why?
|
Professional Practice | 1 | 2011 | 313 | 0.080 |
Why?
|
Diagnosis, Differential | 6 | 2020 | 12965 | 0.080 |
Why?
|
Disease Progression | 7 | 2021 | 13502 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2295 | 0.080 |
Why?
|
Radiography | 2 | 2022 | 6965 | 0.080 |
Why?
|
Carbon Isotopes | 1 | 2009 | 459 | 0.080 |
Why?
|
Publishing | 1 | 2016 | 836 | 0.080 |
Why?
|
Pulmonary Veins | 1 | 2014 | 745 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2020 | 2064 | 0.080 |
Why?
|
Communication | 1 | 2022 | 3849 | 0.080 |
Why?
|
Intermittent Claudication | 1 | 2010 | 306 | 0.080 |
Why?
|
Aldosterone | 1 | 2013 | 868 | 0.080 |
Why?
|
Oxidative Stress | 1 | 2019 | 3106 | 0.080 |
Why?
|
Pain | 1 | 2023 | 5066 | 0.080 |
Why?
|
Cholesterol | 2 | 2021 | 2924 | 0.070 |
Why?
|
Comparative Effectiveness Research | 3 | 2020 | 718 | 0.070 |
Why?
|
Methods | 1 | 2008 | 1074 | 0.070 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 4491 | 0.070 |
Why?
|
Practice Guidelines as Topic | 4 | 2018 | 7475 | 0.070 |
Why?
|
Microspheres | 2 | 2001 | 787 | 0.070 |
Why?
|
Paraganglioma | 1 | 2009 | 142 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2313 | 0.070 |
Why?
|
Cold Temperature | 2 | 2002 | 780 | 0.070 |
Why?
|
Linear Models | 4 | 2015 | 5877 | 0.070 |
Why?
|
Kidney Function Tests | 1 | 2009 | 681 | 0.070 |
Why?
|
Tachycardia, Ventricular | 2 | 2013 | 1303 | 0.070 |
Why?
|
Genotype | 1 | 2021 | 12960 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2932 | 0.070 |
Why?
|
Carotid Stenosis | 1 | 2014 | 878 | 0.070 |
Why?
|
Subcutaneous Fat | 1 | 2010 | 393 | 0.070 |
Why?
|
Angiography | 1 | 2012 | 1605 | 0.070 |
Why?
|
Thrombolytic Therapy | 3 | 2005 | 2108 | 0.070 |
Why?
|
Artificial Intelligence | 4 | 2022 | 2557 | 0.070 |
Why?
|
Bundle-Branch Block | 1 | 2008 | 281 | 0.070 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 361 | 0.070 |
Why?
|
Radiometry | 1 | 2011 | 813 | 0.070 |
Why?
|
Physicians | 2 | 2022 | 4591 | 0.060 |
Why?
|
Dogs | 2 | 2001 | 3841 | 0.060 |
Why?
|
Phenotype | 2 | 2024 | 16546 | 0.060 |
Why?
|
Intra-Abdominal Fat | 1 | 2010 | 608 | 0.060 |
Why?
|
Ultrasonography | 3 | 2015 | 5961 | 0.060 |
Why?
|
Adipose Tissue | 1 | 2017 | 3301 | 0.060 |
Why?
|
Software Validation | 1 | 2005 | 59 | 0.060 |
Why?
|
Young Adult | 8 | 2022 | 58741 | 0.060 |
Why?
|
Mass Screening | 2 | 2015 | 5423 | 0.060 |
Why?
|
Creatinine | 1 | 2010 | 1903 | 0.060 |
Why?
|
Hospitalization | 4 | 2021 | 10790 | 0.060 |
Why?
|
Automation | 2 | 2018 | 580 | 0.060 |
Why?
|
Education, Medical, Graduate | 2 | 2008 | 2363 | 0.060 |
Why?
|
Heart Function Tests | 2 | 2016 | 319 | 0.060 |
Why?
|
Georgia | 1 | 2004 | 190 | 0.060 |
Why?
|
Myoblasts | 1 | 2005 | 232 | 0.060 |
Why?
|
Mortality | 3 | 2021 | 2916 | 0.060 |
Why?
|
Anticholesteremic Agents | 1 | 2011 | 987 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2640 | 0.060 |
Why?
|
North America | 2 | 2020 | 1284 | 0.060 |
Why?
|
Pregnancy | 2 | 2024 | 29749 | 0.060 |
Why?
|
Pandemics | 2 | 2020 | 8624 | 0.050 |
Why?
|
Reference Values | 3 | 2018 | 4925 | 0.050 |
Why?
|
Rest | 1 | 2008 | 914 | 0.050 |
Why?
|
Biological Transport | 3 | 2014 | 2086 | 0.050 |
Why?
|
Gadolinium DTPA | 3 | 2013 | 823 | 0.050 |
Why?
|
Nonlinear Dynamics | 2 | 2017 | 494 | 0.050 |
Why?
|
Heart-Assist Devices | 1 | 2014 | 1291 | 0.050 |
Why?
|
Adolescent | 10 | 2018 | 87810 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2016 | 3127 | 0.050 |
Why?
|
Deoxyglucose | 2 | 2010 | 333 | 0.050 |
Why?
|
Arterial Occlusive Diseases | 1 | 2007 | 752 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Statistics as Topic | 2 | 2012 | 2362 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2017 | 4360 | 0.050 |
Why?
|
Age of Onset | 2 | 2021 | 3301 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2021 | 9530 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Propensity Score | 2 | 2020 | 1928 | 0.050 |
Why?
|
Aspirin | 1 | 2014 | 3364 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2017 | 10344 | 0.050 |
Why?
|
Sulfonamides | 1 | 2011 | 1977 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2696 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2019 | 18137 | 0.050 |
Why?
|
Inflammation Mediators | 2 | 2024 | 1881 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2007 | 2932 | 0.050 |
Why?
|
Sampling Studies | 1 | 2002 | 613 | 0.050 |
Why?
|
Nanoparticles | 1 | 2013 | 1943 | 0.050 |
Why?
|
Medicare | 1 | 2019 | 6786 | 0.050 |
Why?
|
Neoplasms | 2 | 2020 | 22072 | 0.050 |
Why?
|
Classification | 1 | 2021 | 127 | 0.050 |
Why?
|
Chloroquine | 1 | 2022 | 277 | 0.050 |
Why?
|
Diphosphates | 1 | 2020 | 84 | 0.050 |
Why?
|
Interprofessional Relations | 1 | 2006 | 989 | 0.040 |
Why?
|
Mice, Knockout | 4 | 2019 | 14372 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5791 | 0.040 |
Why?
|
Canada | 2 | 2021 | 2128 | 0.040 |
Why?
|
Up-Regulation | 2 | 2024 | 4122 | 0.040 |
Why?
|
Physician's Role | 1 | 2006 | 918 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 2021 | 297 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2003 | 1578 | 0.040 |
Why?
|
Radiation Injuries | 1 | 2007 | 1183 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2015 | 10446 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2021 | 388 | 0.040 |
Why?
|
Organ Size | 1 | 2024 | 2254 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 346 | 0.040 |
Why?
|
Documentation | 2 | 2017 | 893 | 0.040 |
Why?
|
Israel | 1 | 2021 | 722 | 0.040 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2018 | 131 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2005 | 2234 | 0.040 |
Why?
|
Apolipoproteins E | 2 | 2015 | 1436 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2015 | 4673 | 0.040 |
Why?
|
Odds Ratio | 3 | 2016 | 9716 | 0.040 |
Why?
|
Exercise | 2 | 2013 | 5787 | 0.040 |
Why?
|
Finland | 1 | 2019 | 603 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2024 | 998 | 0.040 |
Why?
|
Retinal Vessels | 1 | 2024 | 836 | 0.040 |
Why?
|
Parotid Gland | 1 | 2019 | 175 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2019 | 22023 | 0.040 |
Why?
|
Motion | 1 | 2022 | 779 | 0.040 |
Why?
|
Rupture, Spontaneous | 1 | 2019 | 356 | 0.040 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2019 | 144 | 0.040 |
Why?
|
Mitochondria, Heart | 1 | 2019 | 229 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2021 | 587 | 0.040 |
Why?
|
Death Certificates | 1 | 2018 | 167 | 0.040 |
Why?
|
Models, Animal | 2 | 2015 | 2117 | 0.040 |
Why?
|
Databases, Factual | 2 | 2018 | 8035 | 0.040 |
Why?
|
Consensus | 2 | 2017 | 3113 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 881 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2002 | 609 | 0.040 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2004 | 1485 | 0.040 |
Why?
|
Ephedrine | 1 | 1997 | 52 | 0.040 |
Why?
|
Bone Marrow | 2 | 2019 | 2912 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2019 | 1385 | 0.040 |
Why?
|
Neurons, Efferent | 1 | 1997 | 81 | 0.030 |
Why?
|
Reference Standards | 1 | 2020 | 1004 | 0.030 |
Why?
|
Aging | 1 | 2015 | 8651 | 0.030 |
Why?
|
Rhabdomyolysis | 1 | 2018 | 155 | 0.030 |
Why?
|
Neprilysin | 1 | 2019 | 472 | 0.030 |
Why?
|
Postoperative Period | 1 | 2001 | 1818 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2019 | 488 | 0.030 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2021 | 1110 | 0.030 |
Why?
|
Mesothelioma | 1 | 2002 | 807 | 0.030 |
Why?
|
Muscle Contraction | 1 | 2001 | 1201 | 0.030 |
Why?
|
Blood Glucose | 1 | 2010 | 6381 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 1993 | 9185 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2021 | 843 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2019 | 1850 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4925 | 0.030 |
Why?
|
Transcription Factors | 1 | 2015 | 12103 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2014 | 5209 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 555 | 0.030 |
Why?
|
Thoracic Injuries | 1 | 2018 | 279 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2019 | 18957 | 0.030 |
Why?
|
Safety | 2 | 2013 | 1148 | 0.030 |
Why?
|
Cholesterol, Dietary | 1 | 2015 | 223 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1180 | 0.030 |
Why?
|
Body Weight | 1 | 2006 | 4611 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2262 | 0.030 |
Why?
|
Presynaptic Terminals | 1 | 1997 | 301 | 0.030 |
Why?
|
Tomography, Spiral Computed | 1 | 2016 | 273 | 0.030 |
Why?
|
Expert Testimony | 1 | 2017 | 361 | 0.030 |
Why?
|
Simvastatin | 1 | 2017 | 352 | 0.030 |
Why?
|
Autoradiography | 1 | 2015 | 730 | 0.030 |
Why?
|
Endocardium | 1 | 2015 | 246 | 0.030 |
Why?
|
Norepinephrine | 1 | 1997 | 900 | 0.030 |
Why?
|
Myelopoiesis | 1 | 2015 | 134 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 992 | 0.030 |
Why?
|
Hydrochlorothiazide | 1 | 2014 | 94 | 0.030 |
Why?
|
Curriculum | 1 | 2008 | 3718 | 0.030 |
Why?
|
Aorta | 2 | 2013 | 2039 | 0.030 |
Why?
|
Dependovirus | 1 | 2019 | 709 | 0.030 |
Why?
|
Chronic Disease | 2 | 2003 | 9287 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9962 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2019 | 705 | 0.030 |
Why?
|
Vasomotor System | 1 | 2014 | 207 | 0.030 |
Why?
|
Epinephrine | 1 | 1997 | 791 | 0.030 |
Why?
|
Japan | 1 | 2017 | 1369 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2006 | 5508 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7818 | 0.030 |
Why?
|
Triglycerides | 1 | 2021 | 2476 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2392 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2022 | 2512 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 848 | 0.030 |
Why?
|
Lymphocytes | 1 | 2021 | 2611 | 0.030 |
Why?
|
Pulse | 1 | 2013 | 218 | 0.030 |
Why?
|
Physics | 1 | 2013 | 90 | 0.030 |
Why?
|
Kinetics | 2 | 2010 | 6377 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2893 | 0.030 |
Why?
|
Brain | 1 | 2019 | 26951 | 0.030 |
Why?
|
Child | 5 | 2002 | 79806 | 0.030 |
Why?
|
Zirconium | 1 | 2013 | 107 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2021 | 4775 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2015 | 1753 | 0.020 |
Why?
|
Models, Anatomic | 1 | 2015 | 682 | 0.020 |
Why?
|
Pacemaker, Artificial | 1 | 2017 | 815 | 0.020 |
Why?
|
Autopsy | 1 | 2015 | 1007 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 2 | 2015 | 4048 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 1999 | 1489 | 0.020 |
Why?
|
Foam Cells | 1 | 2011 | 68 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2014 | 15697 | 0.020 |
Why?
|
Diuretics | 1 | 2014 | 613 | 0.020 |
Why?
|
Mice | 5 | 2021 | 81208 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2021 | 3215 | 0.020 |
Why?
|
Longitudinal Studies | 3 | 2013 | 14495 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2017 | 1296 | 0.020 |
Why?
|
Dextrans | 1 | 2013 | 574 | 0.020 |
Why?
|
Microglia | 1 | 2019 | 1351 | 0.020 |
Why?
|
Glucose Transport Proteins, Facilitative | 1 | 2010 | 57 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 2010 | 263 | 0.020 |
Why?
|
Hydrolysis | 1 | 2011 | 665 | 0.020 |
Why?
|
Hexokinase | 1 | 2010 | 125 | 0.020 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2014 | 1446 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2781 | 0.020 |
Why?
|
Learning | 1 | 2019 | 1739 | 0.020 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 461 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3380 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2514 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 42063 | 0.020 |
Why?
|
Motor Activity | 1 | 2019 | 2687 | 0.020 |
Why?
|
Organ Specificity | 1 | 2014 | 1955 | 0.020 |
Why?
|
Spleen | 1 | 2015 | 2298 | 0.020 |
Why?
|
Specialty Boards | 1 | 2011 | 235 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4773 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2015 | 1403 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 2015 | 1097 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 1998 | 1921 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2501 | 0.020 |
Why?
|
Data Collection | 1 | 2018 | 3315 | 0.020 |
Why?
|
Causality | 1 | 2015 | 1242 | 0.020 |
Why?
|
Perioperative Care | 1 | 2016 | 1037 | 0.020 |
Why?
|
Health Status | 1 | 2022 | 4081 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2015 | 2135 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 632 | 0.020 |
Why?
|
3-Iodobenzylguanidine | 1 | 2009 | 114 | 0.020 |
Why?
|
Unnecessary Procedures | 1 | 2012 | 413 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3767 | 0.020 |
Why?
|
Bone and Bones | 1 | 2018 | 2560 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 1570 | 0.020 |
Why?
|
Professional Competence | 1 | 2011 | 431 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5785 | 0.020 |
Why?
|
Computer Simulation | 2 | 2015 | 6218 | 0.020 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 1523 | 0.020 |
Why?
|
Hospitals, General | 1 | 2012 | 795 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7806 | 0.020 |
Why?
|
Cost Savings | 1 | 2013 | 920 | 0.020 |
Why?
|
Postoperative Care | 1 | 2014 | 1479 | 0.020 |
Why?
|
Adiposity | 1 | 2017 | 1858 | 0.020 |
Why?
|
Survivors | 1 | 1998 | 2375 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2011 | 686 | 0.020 |
Why?
|
Syncope | 1 | 2010 | 428 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2754 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1830 | 0.020 |
Why?
|
Calcium Gluconate | 1 | 2005 | 22 | 0.020 |
Why?
|
Hospitals | 1 | 2019 | 3928 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2019 | 3832 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3442 | 0.020 |
Why?
|
Infection Control | 1 | 2013 | 983 | 0.020 |
Why?
|
Triage | 1 | 2013 | 987 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2011 | 830 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4166 | 0.020 |
Why?
|
Sepsis | 1 | 2019 | 2592 | 0.020 |
Why?
|
Stromal Cells | 1 | 2010 | 1326 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4371 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2013 | 1869 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2018 | 5425 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2543 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2015 | 2981 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6498 | 0.010 |
Why?
|
Wound Healing | 1 | 2015 | 2788 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4642 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9073 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9501 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4573 | 0.010 |
Why?
|
Protein Binding | 1 | 2015 | 9335 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5206 | 0.010 |
Why?
|
Lower Extremity | 1 | 2010 | 1194 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2001 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2010 | 6216 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2012 | 2283 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 3201 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9994 | 0.010 |
Why?
|
Pleura | 1 | 2002 | 244 | 0.010 |
Why?
|
Catheter Ablation | 1 | 2014 | 2758 | 0.010 |
Why?
|
Recurrence | 1 | 2013 | 8482 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2116 | 0.010 |
Why?
|
Infant | 1 | 2002 | 36060 | 0.010 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2005 | 613 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 2002 | 402 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6479 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3323 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 3986 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2010 | 3959 | 0.010 |
Why?
|
Cytokines | 1 | 2011 | 7343 | 0.010 |
Why?
|
Quality Improvement | 1 | 2011 | 3836 | 0.010 |
Why?
|
Cardiac Output | 1 | 1998 | 838 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12766 | 0.010 |
Why?
|
Physical Exertion | 1 | 1998 | 662 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1998 | 1146 | 0.010 |
Why?
|
Clinical Competence | 1 | 2008 | 4783 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 1999 | 1925 | 0.000 |
Why?
|
Combined Modality Therapy | 1 | 1999 | 8552 | 0.000 |
Why?
|